Adrenaline, mepivacaine
Sold as Scandonest special
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| The Dental Warehouse (Pty) Ltd | Scandonest special | 2 % | Y0421 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Scandonest 2 % special EACH 1,80 ml SOLUTION CONTAINS ADRENALINE 0,018 mg MEPIVACAINE HYDROCHLORIDE 36 mg | 2 % | Y0421Y/4/421 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Adrenaline
- when intended for injection.
Consolidated Schedules 06 July 2026, line 5148
S4: Mepivacaine
Consolidated Schedules 06 July 2026, line 7064
S3: Adrenaline
- ophthalmic preparations thereof, when intended for glaucoma.
Consolidated Schedules 06 July 2026, line 3122
S2: Adrenaline
- ophthalmic preparations when intended for glaucoma, and
- preparations for injection. (S3, S4)
Consolidated Schedules 06 July 2026, lines 1561 to 1565
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.